Biotech Stock Roundup: NVAX, FULC Up on Deals With SNY, Updates From MRNA, BMY
https://www.zacks.com/stock/news/2275062/biotech-stock-roundup-nvax-fulc-up-on-deals-with-sny-updates-from-mrna-bmy?cid=CS-ZC-FT-analyst_blog|stock_roundup-2275062
May 16, 2024 - Novavax, Inc (NVAX) and Fulcrum Therapeutics, Inc (FULC) are in the spotlight following license agreements with pharma giant Sanofi.
0
Bristol Myers (BMY) Fails to Meet Goal in Opdivo NSCLC Study
https://www.zacks.com/stock/news/2272954/bristol-myers-bmy-fails-to-meet-goal-in-opdivo-nsclc-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2272954
May 13, 2024 - Bristol Myers' (BMY) late-stage label-expanding study evaluating the Opdivo/Yervoy combination fails to meet the primary endpoint of progression-free survival in unresectable stage III NSCLC.
0
2 Beaten-Down Stocks to Buy and Hold for 10 Years
https://www.fool.com/investing/2024/05/10/2-beaten-down-stocks-to-buy-and-hold-for-10-years/?source=iedfolrf0000001
May 10, 2024 - They offer plenty of upside and solid dividend growth.
0
A Look at Pharma ETFs Post Q1 Earnings
https://www.zacks.com/stock/news/2269782/a-look-at-pharma-etfs-post-q1-earnings?cid=CS-ZC-FT-etf_news_and_commentary-2269782
May 07, 2024 - Many industry bigwigs reported solid results, with some beating on earnings or revenues or both.
0
Biotech Stock Roundup: BIIB, BMY's Q1 Earnings, INCY's Acquisition & Updates from VRTX
https://www.zacks.com/stock/news/2262685/biotech-stock-roundup-biib-bmy-s-q1-earnings-incy-s-acquisition-updates-from-vrtx?cid=CS-ZC-FT-analyst_blog|earnings_article-2262685
Apr 25, 2024 - Biogen (BIIB) and Bristol Myers (BMY) are in focus following Q1 earnings announcement.
0
Bristol Myers (BMY) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates (Revised)
https://www.zacks.com/stock/news/2262549/bristol-myers-bmy-q1-earnings-taking-a-look-at-key-metrics-versus-estimates-revised?cid=CS-ZC-FT-fundamental_analysis|nfm-2262549
Apr 25, 2024 - While the top- and bottom-line numbers for Bristol Myers (BMY) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
0
Bristol-Myers (BMY) Q1 Loss Narrower Than Expected, Sales Beat
https://www.zacks.com/stock/news/2262623/bristol-myers-bmy-q1-loss-narrower-than-expected-sales-beat?cid=CS-ZC-FT-analyst_blog|earnings_article-2262623
Apr 25, 2024 - Bristol-Myers' (BMY) first-quarter 2024 loss is narrower than estimated. Sales surpass the consensus mark on the back of Eliquis, Reblozyl and Opdualag's encouraging performance. However, Opdivo sales disappoint.
0
2seventy bio (TSVT) Rises More Than 50% in 3 Months: Here's Why
https://www.zacks.com/stock/news/2257012/2seventy-bio-tsvt-rises-more-than-50-in-3-months-here-s-why?cid=CS-ZC-FT-analyst_blog|price_surge_/_plunge-2257012
Apr 17, 2024 - The FDA's recent nod to 2seventy bio's (TSVT) Abecma in earlier lines of treatment for relapsed/refractory multiple myeloma is a positive. Also, the R&D asset divestiture to Regeneron is saving costs.
0
2 High-Yield Dividend Stocks to Buy and Hold for 10 Years
https://www.fool.com/investing/2024/04/17/2-high-yield-dividend-stocks-to-hold-for-10-years/?source=iedfolrf0000001
Apr 17, 2024 - These income stocks look like good options at current levels.
0
Bristol Myers Squibb (BMY) Advances While Market Declines: Some Information for Investors
https://www.zacks.com/stock/news/2255656/bristol-myers-squibb-bmy-advances-while-market-declines-some-information-for-investors?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v1-2255656
Apr 15, 2024 - Bristol Myers Squibb (BMY) closed the most recent trading day at $48.51, moving +0.48% from the previous trading session.
0
Page 1>